Suppr超能文献

老年收缩性心力衰竭的治疗:基于证据的综述。

Treatment of systolic heart failure in the elderly: an evidence-based review.

机构信息

Midwestern University, Downers Grove, IL, USA.

出版信息

Ann Pharmacother. 2010 Oct;44(10):1604-14. doi: 10.1345/aph.1P128. Epub 2010 Sep 14.

Abstract

OBJECTIVE

To review relevant literature supporting the use of β-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, digoxin, aldosterone antagonists, and vasodilators in the management of heart failure in an elderly patient population aged ≥65 years.

DATA SOURCES

PubMed, EMBASE, and MEDLINE searches (January 1960-April 2010) were utilized to identify primary literature using the key terms heart failure, treatment, and elderly. Additionally, reference citations from publications identified were utilized, as well as the American College of Cardiology/American Heart Association (ACC/AHA) Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult.

STUDY SELECTION AND DATA EXTRACTION

Primary and tertiary literature, including subgroup analyses, published in English and relating to the use of pharmacotherapy in the treatment of systolic heart failure in the elderly was reviewed.

DATA SYNTHESIS

The aging of the US population is creating a higher prevalence of systolic heart failure in the elderly. Most clinical trials have established the mortality and morbidity benefit of pharmacotherapy in heart failure in nonelderly patients; however, the current ACC/AHA guidelines do not clearly delineate this benefit in persons ≥65 years of age.

CONCLUSIONS

Clinical trial data, based on limited numbers of individuals aged ≥65 years, suggest that use of β-blockers, ACE inhibitors, ARBs, aldosterone antagonists, and vasodilators (hydralazine/nitrates) have similar mortality benefit to that observed in younger patients. As supported in the ACC/AHA guidelines, these agents should be prescribed with clinical judgment to all elderly patients, with close monitoring for adverse events. Future clinical trials with greater inclusion of patients ≥65 years will help to elucidate the magnitude of benefits of optimal pharmacotherapy on mortality and morbidity rates in this population.

摘要

目的

回顾支持在≥65 岁老年患者人群中使用β受体阻滞剂、血管紧张素转换酶(ACE)抑制剂、血管紧张素受体阻滞剂(ARB)、利尿剂、地高辛、醛固酮拮抗剂和血管扩张剂治疗心力衰竭的相关文献。

资料来源

使用关键词“心力衰竭、治疗和老年”,对 PubMed、EMBASE 和 MEDLINE 数据库(1960 年 1 月-2010 年 4 月)进行了初级文献检索。此外,还利用了出版物中的参考文献以及美国心脏病学会/美国心脏协会(ACC/AHA)的《成人慢性心力衰竭诊断与治疗指南》。

研究选择和资料提取

回顾了初级和三级文献,包括亚组分析,文献均为英文,且与老年人心力衰竭药物治疗的使用相关。

资料综合

美国人口老龄化导致老年人心力衰竭的发病率增加。大多数临床试验已经证实了非老年患者药物治疗心力衰竭的死亡率和发病率获益;然而,目前的 ACC/AHA 指南并没有明确界定≥65 岁患者的这一获益。

结论

基于少数≥65 岁患者的临床试验数据表明,β受体阻滞剂、ACE 抑制剂、ARB、醛固酮拮抗剂和血管扩张剂(肼屈嗪/硝酸盐)的使用与年轻患者一样具有相似的死亡率获益。正如 ACC/AHA 指南所支持的,这些药物应根据临床判断开给所有老年患者,密切监测不良反应。未来包含更多≥65 岁患者的临床试验将有助于阐明最佳药物治疗对该人群死亡率和发病率的获益程度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验